TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21397770
Drug: Vehicle administered
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle administered twice daily for 3 days
Study: 16781589
Drug: Traumeel S
Normalized name: Traumeel S Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traumeel S ointment
Study: 16781589
Drug: Diclofenac 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 1% gel
Study: 7742723
Drug: Oral folic
Normalized name: folic acid Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral folic acid (5 mg) daily for 6 months
Study: 7742723
Drug: Placebo (similar-appearing)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (similar-appearing) daily for 6 months
Study: 7742723
Drug: Oral folic
Normalized name: folic acid Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral folic acid (5 mg)
Study: 2201724
Drug: Zopiclone (ZOP,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone (ZOP, 7.5 mg)
Study: 2201724
Drug: Triazolam (TRZ,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (TRZ, 0.25 mg) + Alcohol (0.8 g/kg)
Study: 2201724
Drug: Zopiclone (ZOP,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone (ZOP, 7.5 mg) + Alcohol (0.8 g/kg)
Study: 7018605
Drug: Standard formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard formulation
Study: 7018605
Drug: Alternative formulation
Normalized name: Yellow fever vaccine live - alternative formulation for vaccine shortage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative formulation
Study: 19702927
Drug: Family‐focused therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family‐focused therapy (FFT)
Study: 11509190
Drug: Smoked marijuana
Normalized name: Picea mariana resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoked marijuana (8.4 and 16.9 mg THC)
Study: 27609846
Drug: Postoperative intravenous
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative intravenous parecoxib sodium followed by oral celecoxib
Study: 27609846
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with opioids as rescue treatment
Study: 23725316
Drug: Biological management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological management of caries with best practice prevention
Study: 20578610
Drug: Clonidine tablet
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine tablet at the dose of 5 microg/kg
Study: 18400709
Drug: Dark chocolate
Normalized name: Ensure Original Dark Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dark chocolate and cocoa (37-g dark chocolate bar and 8 ounces of artificially sweetened cocoa beverage daily for 6 weeks
Study: 18400709
Drug: Placebo (similar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (similar placebo products daily for 6 weeks)
Study: 16102908
Drug: Sustained-release methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release methylphenidate
Study: 12527318
Drug: Painful infusion
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Painful infusion of hypertonic saline in the FDI muscle
Study: 19299805
Drug: Lidocaine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (5 mg/kg)
Study: 10588558
Drug: Amantadine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine (2.5 mg/kg)
Study: 29781900
Drug: Nonablative fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonablative fractional laser (NAFL) treatment on one half of the face
Study: 29781900
Drug: Low-dose isotretinoin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose isotretinoin (10 mg/day)
Study: 22757665
Drug: NAFL treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAFL treatment
Study: 23946152
Drug: Ritonavir-boosted danoprevir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir-boosted danoprevir (DNVr) 100/100 mg twice/day
Study: 23946152
Drug: Methadone maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone maintenance therapy (MMT) alone
Study: 15917111
Drug: PCECV (Purified
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCECV (Purified Chick Embryo Cell Vaccine) administered intradermally at 0.1 mL with antigen corresponding to 0.32 IU per intramuscular dose
Study: 15917111
Drug: Current WHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current WHO recommendations for vaccine potency (2.5 IU per intramuscular dose)
Study: 8600871
Drug: Home program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home program of physical therapy (6-week program including ROM exercises, low resistance isometric and eccentric exercises of hip abductors)
Study: 8600871
Drug: Home program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home program of physical therapy (all programs for group B)
Study: 1817942
Drug: Rectal Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rectal Midazolam sedation
Study: 1817942
Drug: Oral Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Midazolam sedation
Study: 7258126
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid supplementation (1.8 g daily for 10 children, 1.5 g daily for 10 children)
Study: 31173468
Drug: Antiviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral treatment for HBV (HBV DNA < 20 IU/mL after 48 weeks)
Study: 31173468
Drug: Antiviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral treatment for HCV (SVR-12)
Study: 31173468
Drug: Post-treatment PRO
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment PRO scores
Study: 23988398
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (blinded random allocation to trial treatment or placebo)
Study: 22264599
Drug: Cognitive adaptation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive adaptation training combined with assertive community treatment (CAT+ACT)
Study: 22264599
Drug: Assertive community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assertive community treatment alone (ACT)
Study: 17211096
Drug: ED-71 treatment
Normalized name: Ed-APAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: ED-71 treatment for 12 months
Study: 17211096
Drug: ED-71 treatment
Normalized name: Ed-APAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: ED-71 treatment
Study: 15526112
Drug: Electrogalvanic stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrogalvanic stimulation (EGS) twice a week
Study: 15526112
Drug: Local injection
Normalized name: Sclerosing agents for local injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injection of 40-mg triamcinolone acetonide mix with 1 ml 2% lidocaine
Study: 11564134
Drug: Levocetirizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocetirizine (10 mg)
Study: 7843964
Drug: 3% NaCl
Normalized name: LVP solution Dextrose 5% with 0.3% NaCl intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% NaCl solution baths
Study: 3152422
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside with oral captopril pretreatment
Study: 28985328
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (systolic blood pressure target <120 mm Hg)
Study: 28985328
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (systolic blood pressure target <140 mm Hg)
Study: 28985328
Drug: Overall model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall model (both treatment arms)
Study: 25352300
Drug: lamivudine plus
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lamivudine plus adefovir dipivoxil (ADV) combination therapy (COMBO)
Study: 25352300
Drug: lamivudine monotherapy
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lamivudine monotherapy (MONO)
Study: 25352300
Drug: lamivudine monotherapy
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lamivudine monotherapy (MONO) with early virological response
Study: 23314393
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg amphetamine (AMPH)
Study: 11928585
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tolerance test (75 g)
Study: 11928585
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tolerance test and glycemia at 120 min exceeding 11.1 mmol/l
Study: 1948658
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no steroids)
Study: 2877576
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg intravenous famotidine
Study: 2877576
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg intravenous famotidine
Study: 2877576
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oral famotidine
Study: 16159618
Drug: ASHMI group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASHMI group (oral ASHMI capsules and prednisone placebo tablets)
Study: 16159618
Drug: Prednisone group
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone group (oral prednisone tablets and ASHMI placebo capsules)
Study: 12669132
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of n-3 polyunsaturated fatty acids (PUFAs)
Study: 12669132
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of n-3 PUFAs
Study: 12669132
Drug: Additional statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional statin treatment
Study: 10550467
Drug: Alendronate 10
Normalized name: ALENDRONATE 10MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 10 mg once daily for 1 year
Study: 8727863
Drug: Sulfadiazine 500
Normalized name: sulfadiazine 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadiazine 500 mg/Trimethoprim 160 mg twice daily
Study: 8348278
Drug: Active laser
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active laser treatment (CB Medico Master III 830 nm Ga As AL diode)
Study: 8348278
Drug: Dummy laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dummy laser treatment
Study: 3528278
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline plus hydrocortisone (100 mg daily)
Study: 3528278
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (1 l/day)
Study: 17512232
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (rhGH) 0.019 mg kg(‐1) day(‐1) for 6 days
Study: 15459211
Drug: Doxorubicin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 60 mg/m² plus cisplatin 50 mg/m² every 3 weeks
Study: 15459211
Drug: Doxorubicin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 60 mg/m²
Study: 9210675
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg orally every 12 hours
Study: 9210675
Drug: Ciprofloxacin 400
Normalized name: ciprofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 400 mg intravenously
Study: 3689614
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 0.8 mg (group A)
Study: 3689614
Drug: i.m. papaveretum
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. papaveretum 10 mg (group B)
Study: 29451991
Drug: βHB (d‐β‐hydroxybutyrate)
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: βHB (d‐β‐hydroxybutyrate) beverage (11.38 g)
Study: 11193281
Drug: Protein C
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein C and tissue factor-pathway inhibitor
Study: 9033197
Drug: maximal regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: maximal regimen including daily clofazimine
Study: 9033197
Drug: maximal regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: maximal regimens including daily rifampicin
Study: 1670744
Drug: Doxazosin (4.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (4.7 mg daily)
Study: 1670744
Drug: Prazosin (6.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (6.7 mg daily)
Study: 6138086
Drug: Midazolam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (15 mg p.o.)
Study: 28355198
Drug: F130 (130
Approvals — FDA: no, EMA: no, PMDA: no
Description: F130 (130 mg of OPN/L)
Study: 28355198
Drug: F65 (65
Approvals — FDA: no, EMA: no, PMDA: no
Description: F65 (65 mg of OPN/L)
Study: 25151265
Drug: Ablation or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablation or silencing of GABAergic neurons or disruption of metabotropic GABA receptor 1 and 2 (GABA B R1/2) signaling in astrocytes
Study: 22300419
Drug: Midazolam pharmacokinetics
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam pharmacokinetics model based on infants, toddlers, and adults (model 1)
Study: 22300419
Drug: Midazolam pharmacokinetics
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam pharmacokinetics model based on children and adolescents (model 2)
Study: 17721040
Drug: Existing drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Existing drugs (e.g., non‐steroidal anti‐inflammatory drugs, vitamins, and imatinib mesylate)
Study: 16586188
Drug: 4 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 micrograms 1‐alpha‐hydroxyvitamin D(2) (1‐alpha D(2)) administered daily for 24 months
Study: 16586188
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered daily for 24 months
Study: 9858106
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment (n = 18)
Study: 9858106
Drug: Sulfonylurea treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylurea treatment (n = 16)
Study: 7890127
Drug: Parenteral amino
Normalized name: parenteral amino acid 7 % comb no.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral amino acid preparation causing high plasma amino acid levels
Study: 7890127
Drug: Parenteral amino
Normalized name: parenteral amino acid 7 % comb no.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral amino acid preparation with normal plasma aminogram levels
Study: 26280156
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MMF) 0.1% ointment, applied once daily for 5 days per week for 4 weeks, then on alternate days for 4 weeks, then twice weekly for 4 weeks (group A)
Study: 26280156
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MMF) 0.1% ointment, applied for five consecutive days per week for the entire treatment duration (group B)
Study: 16021530
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation at 80 mg
Study: 16021530
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation at 200 mg
Study: 16021530
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation at 400 mg
Study: 12548078
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (10 mg/d) for 14 days
Study: 3847486
Drug: Cefotaxime (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (50 mg/kg/dose every 6 hours)
Study: 3847486
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (ampicillin and chloramphenicol in standard doses)
Study: 3847486
Drug: Cefotaxime and
Normalized name: cefotaxime and beta-lactamase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime and Standard therapy
Study: 10588216
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (10 mg/day)
Study: 7979853
Drug: Nicotine nasal
Normalized name: nicotine Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine nasal spray (0.5 mg per single spray)
Study: 4916870
Drug: Levamisole (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (single oral dose)
Study: 4916870
Drug: Levamisole (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (single dose)
Study: 4916870
Drug: Piperazine citrate
Normalized name: Piperazine Citrate
DrugBank: Piperazine (DB00592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piperazine citrate (single dose)
Study: 23882458
Drug: 0.2% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% chlorhexidine gel
Study: 17693145
Drug: L-Carnitine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Carnitine (2 g daily for 180 days)
Study: 12134281
Drug: Pergolide (2.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pergolide (2.25 mg/day)
Study: 15762
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 mg thrice daily with meals)
Study: 15762
Drug: Prindolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prindolol (5 mg thrice daily with meals)
Study: 15762
Drug: Methyclothiazide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyclothiazide (5 mg with breakfast)
Study: 15762
Drug: Propranolol doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol doses (120 mg, 60 mg, 40 mg with meals)
Study: 15762
Drug: Metoprolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (200 mg with breakfast, 100 mg with breakfast and evening meal)
Study: 15762
Drug: Prindolol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prindolol (30 mg, 15 mg, 10 mg with meals)
Study: 31368283
Drug: Blade needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blade needle therapy (longitudinal cutting along the musculoaponeurotic layer) applied to tender points of the head and neck, treatment conducted once every 3 days for 15 days.
Study: 31368283
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group receiving Flunarizine Hydrochloride capsules (10 mg) once every night for 15 days.
Study: 25944513
Drug: Hypocapnia trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypocapnia trial (voluntary hyperventilation, minute ventilation = 31 L min(‐1))
Study: 25944513
Drug: Control trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control trial (spontaneous breathing, minute ventilation = 14 L min(‐1))
Study: 21971743
Drug: Lying down
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lying down immediately after spinal anesthesia (Group L)
Study: 19463339
Drug: Intracellular calcium
Normalized name: ACTIVIN RECEPTOR TYPE IIA (SYNTHETIC HUMAN EXTRACELLULAR DOMAIN-CONTAINING FRAGMENT) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (SYNTHETIC HUMAN HEAVY CHAIN FC FRAGMENT), DIMER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracellular calcium modulator as adjunct to primary PCI
Study: 2571021
Drug: GHB (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB (50 mg/kg, orally in a syrup preparation)
Study: 2571021
Drug: Control syrup
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control syrup (no active treatment)
Study: 1277749
Drug: Arginine vasopressin
Normalized name: 1-deamino-8-D-arginine vasopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine vasopressin infusion at 12.5 units/min for 1 h
Study: 1277749
Drug: Arginine vasopressin
Normalized name: 1-deamino-8-D-arginine vasopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine vasopressin infusion at 25 units/min for 1 h
Study: 1277749
Drug: Arginine vasopressin
Normalized name: 1-deamino-8-D-arginine vasopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine vasopressin infusion (both doses)
Study: 27978602
Drug: Immediate Implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate Implant (IMI)
Study: 27978602
Drug: Delayed Implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed Implant (DI)
Study: 23591282
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin (BTX) injections (8 × 12.5 U)
Study: 23591282
Drug: Saline injections
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injections (8 × 0.5 mL)
Study: 16450086
Drug: Aprepitant (A)
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant (A) regimen: A 125 mg p.o. plus ondansetron (O) 32 mg and dexamethasone (D) 12 mg on day 1; A 80 mg and D 8 mg once daily on days 2-3; and D 8 mg on day 4.
Study: 16450086
Drug: Control regimen:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control regimen: Ondansetron (O) 32 mg i.v. and dexamethasone (D) 20 mg p.o. on day 1; D 8 mg twice daily on days 2-4.
Study: 9140160
Drug: Low-dose UDCA
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose UDCA (10 mg/kg/day)
Study: 9140160
Drug: High-dose UDCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose UDCA (20 mg/kg/day)